Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I for the treatment of cardiovascular, pulmonary diseases, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a novel prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases, such as antiphospholipid syndrome. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System, as well as collaboration with the Pulmonary and Vascular Research Institute (PVRI). Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden.
Metrics to compare | CRNOSb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRNOSbPeersSector | |
---|---|---|---|---|
P/E Ratio | −27.7x | −19.1x | −0.4x | |
PEG Ratio | - | −0.41 | 0.00 | |
Price/Book | 18.1x | 10.9x | 2.6x | |
Price / LTM Sales | 40.0x | 83.1x | 2.9x | |
Upside (Analyst Target) | - | −43.1% | 54.4% | |
Fair Value Upside | Unlock | −20.6% | 9.3% | Unlock |